Moichor

About Moichor

Moichor is a veterinary diagnostics company leveraging artificial intelligence to modernize animal healthcare. Founded in 2019 by Matthew Chen, Shevy Karbasi, and Thanh Le, the company emerged from an initial concept at Penn State University to improve human blood tests. The founders pivoted to veterinary medicine after identifying significant challenges and outdated methods in avian and reptile diagnostics.

The company's core business revolves around providing advanced diagnostic services to veterinarians across the United States. Moichor utilizes a combination of AI, computer vision, and expert analysis from pathologists to deliver faster and more precise results for a wide range of animals, including exotic species that traditional analyzers struggle with. Its business model includes both a reference laboratory for send-out tests and an in-clinic device, the 'Pathview', which provides real-time hematology and cytology results. This dual approach allows veterinary clinics to choose the service that best fits their workflow, with no contractual commitments required.

Moichor's primary service is its AI-powered Complete Blood Count (CBC), which it pioneered for exotic animals in 2020. The technology analyzes high-throughput images of blood smears, using machine learning to classify cells with greater accuracy and less variability than manual methods. This system can detect morphological abnormalities that other systems might miss. Beyond CBCs, the company offers a comprehensive suite of services including chemistry panels, cytology, and specialized tests like endocrinology and parasitology. A key differentiator is the development of the world's largest species-specific reference interval library, aiming to provide more tailored and accurate pathology results for every patient.

Since its inception, Moichor has secured significant funding, including a seed round in 2021 led by Neotribe Ventures after completing the Y Combinator Winter 2021 program. This capital has fueled the expansion of its automated pathology services and the development of its point-of-care technology. The company serves a growing number of clinics and aims to disrupt the multi-billion dollar diagnostic market dominated by larger incumbents.